Skip to main content
Equibles
RYTM logo

RYTM

Rhythm Pharmaceuticals, Inc.
$109.69 -0.27 (-0.25%) At close · Jul 15
Market Cap
$7.48B
Shares
68,532,607

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$109.69 Open$109.04 Day$107.30–110.69 52W$74.50–122.20 Avg vol 30d840K Short int9.7M · 14.1% float · 7.6d Short vol73% Last earningsMay 5, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 5
Up next
Next earnings call
Aug 4, 2026 Est · unconfirmed · in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 5, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 16.5 · calm Equity put/call 0.62
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +11%
      above
      Price vs 50-day avg +13%
      above
      RSI (14) 59
      neutral
      MACD trend Negative
      52-week position 74%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return +15%
      trailing
      6-month return +4%
      trailing
      YTD return +2%
      this year
      Relative strength −7%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $97 › 200d $99 — 200d above 50d
      Institutional flow Accumulating
      20 of 286 funds reported for Jun 30 · net +198.3K sh shares · +6 new
      Insider flow Distributing
      Net -$428.1K over 90 days · 100% sells
      Short interest Rising
      14.10% of float · ▲ +20.7% MoM · 7.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      286 holders — near 3-yr high, broad support
      Squeeze score 80
      high risk · 0–100
      Fundamentals
      Fair
      EPS growth +28%
      Y/Y
      Free cash flow $-116.6M
      Balance sheet $53.9M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 47%
      annualized · 1-yr
      Max drawdown −36%
      past year
      ATR 4.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +11% Bullish
      Price vs 50-day avg
      +13% Bullish
      RSI (14)
      59 Neutral
      MACD trend
      Negative Bearish
      52-week position
      74% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $97 › 200d $99 — 200d above 50d
      Institutional flow Accumulating
      20 of 286 funds reported for Jun 30 · net +198.3K sh shares · +6 new
      Insider flow Distributing
      Net -$428.1K over 90 days · 100% sells
      Short interest Rising
      14.10% of float · ▲ +20.7% MoM · 7.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      286 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $75 Now $110 · 74% 52-wk high $122
      vs 200-day avg +11% vs 50-day avg +13%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      sales reps deployed 42 Q1 FY2026 call —
      start forms 150 first six weeks since approval call —
      unique prescribers for acquired HO 110 first six weeks of launch call —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      RYTM
      Rhythm Pharmaceuticals, Inc.
      this stock
      		$7.48B +2.5% +227.6% — 14.1%
      ONC
      BeOne Medicines Ltd.
      		 $449.85B +2.5% +22179.2% 915.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $121.09B +5.2% +46.2% 28.3 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.66B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $53.96B +2.6% — — 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      290
      % held
      103.5%
      Reported
      20 of 286
      Top holder
      RA CAPITAL MANAGEMENT, L.…
      Held Float
      View
      Held by Funds
      Fund positions
      319
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      9.7M
      Days to cover
      7.6d
      Change
      +1.7M sh
      View
      Short Volume
      Short vol %
      73%
      As of
      Jul 15, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      22.3K
      Value
      $2.4M
      As of
      Jun 29, 2026
      View
      Off-Exchange
      Off-exchange %
      60.8%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$428.1K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $189.8M
      Net income (FY)
      $-196.5M
      EPS diluted
      $-3.11
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 25, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $3.6M
      Shares
      37.0K
      Filed
      Jun 22, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      RYTM -4.1% +15.1% +3.5% -1.2% +2.5%
      SPY +1.3% -0.2% +10.1% +1.1% +10.7%
      vs SPY -5.4% +15.2% -6.6% -2.3% -8.2%
      Key facts CIK 1649904 CUSIP 76243J105 13F (30d) 20 filings 19 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)